148 related articles for article (PubMed ID: 1601332)
1. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
Markman M; Berek JS; Blessing JA; McGuire WP; Bell J; Homesley HD
Gynecol Oncol; 1992 Apr; 45(1):3-8. PubMed ID: 1601332
[TBL] [Abstract][Full Text] [Related]
2. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.
Guastalla JP; Lhomme C; Kerbrat P; Mayer F; Namer M; Goupil P; Charrot P; Heron JF; Chazard M; Richard I
Ann Oncol; 1994 Feb; 5(2):127-32. PubMed ID: 8186155
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Berek JS; Markman M; Blessing JA; Kucera PR; Nelson BE; Anderson B; Hanjani P
Gynecol Oncol; 1999 Jul; 74(1):48-52. PubMed ID: 10385550
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
Nardi M; Cognetti F; Pollera CF; Giulia MD; Lombardi A; Atlante G; Calabresi F
J Clin Oncol; 1990 Jun; 8(6):1036-41. PubMed ID: 2189953
[TBL] [Abstract][Full Text] [Related]
11. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
Markman M; Reichman B; Hakes T; Jones W; Lewis JL; Rubin S; Almadrones L; Hoskins W
J Clin Oncol; 1991 Oct; 9(10):1801-5. PubMed ID: 1919630
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal carboplatin: rationale and experience.
Speyer JL; Sorich J
Semin Oncol; 1992 Feb; 19(1 Suppl 2):107-13. PubMed ID: 1411621
[TBL] [Abstract][Full Text] [Related]
13. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy.
Menczer J; Ben-Baruch G; Modan M; Brenner H
Cancer; 1989 Apr; 63(8):1509-13. PubMed ID: 2924259
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer.
Markman M; Reichman B; Hakes T; Rubin S; Jones W; Lewis JL; Barakat R; Curtin J; Almadrones L; Hoskins W
Gynecol Oncol; 1992 Dec; 47(3):353-7. PubMed ID: 1473749
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
Fujiwara K; Markman M; Morgan M; Coleman RL
Gynecol Oncol; 2005 Apr; 97(1):10-5. PubMed ID: 15790431
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
Piver MS; Recio FO; Baker TR; Driscoll D
Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]